Continuous and segmented microfluidic strategies are being used as uniqe methods to drive the self-assembly of novel pendant polymer (e.g., hyaluronic acid-adamantane & cationic β-cyclodextrin) and polyrotaxane systems as therapeutics to facilitate gene and drug delivery. Currently targeted diseases are wide-ranging, including a variety of cancers and Niemann-Pick Type C disease. My strategies include developing materials poised to avoid many problematic factors in the field (e.g. efficiency, biocompatibility, and biodegradability). Further, microfluidic-mediated control of nanoparticle properties such as size, polydispersity, and complexation/decomplexation ability has been published and is presently being explored more rigorously.
Due to the general lack of rational methods to guide protein crystallization, schemes are in development for facilitating protein crystallization and allowing structural information to be obtained for previously "uncrystallizable" proteins. Affinity ligands provide the scaffold for templated crystallization in bulk solution (left) and at monolayer interfaces (right).